AuthorMike ArchivesCategories |
Back to Blog
Icad Mammography11/13/2021
ETLeading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlogFuji to distribute iCAD digital mammography products FUJIFILM Medical Systems USA, Inc. C-View software progresses early breast cancer detection further by generating a 2D image directly from the tomosynthesis data, lowering patient radiation dose and compression time, with the added benefit of greater patient comfort.Press Release iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography Published: Sept. Clinically proven to increase invasive cancer detection 2-6 and decrease recall rates 2,4,5,6,7 compared with 2D alonejust like our original 3D mammogram.
Icad Mammography Free Event WillWe are committed to women and helping protect their health. Visit this link to register.GE Healthcare Mammography - Exceptional Care with Confidence. Titled “ Pandemic Recovery: How New Technology Can Support Clinicians and Patients in the Aftermath of COVID-19,” the free event will take place on September 14, 2021, at 7 pm ET/4 pm PT. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host an educational roundtable event to help clinicians and their facilities recover from the impact of the COVID-19 pandemic. 09, 2021 (GLOBE NEWSWIRE) - iCAD, Inc. (Nashua, NH) have signed an agreement under which Fuji will offer iCADs SecondLook Digital and TotalLook products optimized for the Fuji Computed Radiography for Mammography (FCR m ) NASHUA, N.H., Sept.Icad Mammography Software Progresses Early“Mammography dropped by as much as 92% in some areas at the height of the pandemic, creating a massive mammography backlog, 1 but as more Americans are becoming vaccinated, women have begun to return to imaging centers for cancer screening. The technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the “Clinicians are in need of new solutions to navigate today’s challenges,” said Stacey Stevens, President of iCAD. PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, PACS, and image storage systems.iCAD has launched ProFound AI Risk for digital breast tomosynthesis (DBT), or 3D mammography, which offers greater accuracy and ethnically inclusive precision screening. How to get around fortinet“We are typically a very high-volume practice reading more than 50,000 screening mammograms per year, and the addition of a ‘second reader’ via ProFound AI helped our radiologists absorb our increased workload. Just before that time, in mid-2019, we converted our practice to 100% tomosynthesis,” said Dr. Nepute, MD, Radiologist, IU Health Frankfort, IU Health Arnett, IU Health White Memorial, Lafayette, INNeesha Patel, MD, Director of Breast Imaging and Residency and Clerkship Academic Director, Kings County Hospital, SUNY DownstateRakesh Patel, MD (Moderator), Managing Partner, Precision Cancer Specialists, Inc. Chair, Breast Cancer Program, Good Samaritan Hospital, Los Gatos, CABarry Rosen, MD FACS, Medical Director, Advocate Good Shepherd Hospital, Breast Center Assistant Professor, University of Illinois College of Medicine“We began the implementation of ProFound AI at the end of 2019 and completed the rollout in the middle of the pandemic, in mid-2020. ![]() Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent its confidence that a detection or case is malignant. ProFound AI helps to boost our confidence - it’s akin to someone looking over my shoulder while I read, so I know I’m not the only one looking at these images.”Built with the latest in deep-learning technology, ProFound AI for DBT rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities. “We have a significant backlog—in fact, we’re booking screenings into January and February of 2022 right now. “We are at least 10% above our pre-pandemic levels at this time, which has led to feelings of burnout by many of our radiologists, but ProFound AI has been a reliable backup for our team, as it helps to ensure we’re performing at an optimum level and calling back only those patients who need additional imaging.”“We are now busier than ever, as many patients who didn’t get screened during the pandemic are coming back,” said Dr. 2“We saw our volume of mammography screenings decrease significantly during the pandemic however, since this past spring, our volume has skyrocketed,” said Dr. ![]() Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company and other risks detailed in the Company’s filings with the Securities and Exchange Commission. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For more information, visit and Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of the Company’s products and future prospects for the Company’s technology platforms and products. 1 ProFound AI Version 3.0 was developed using over five million images from 30,000 cases, including almost 8,000 biopsy-proven cancers, and validated on approximately one million images from 3,500 cases that included 1,200 biopsy-proven cancers.ICAD’s Breast Health Solutions suite also includes ProFound AI for 2D Mammography, ProFound AI Risk, the world’s first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram, 4 and software to evaluate breast density.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. Saved by the max reservationsFor additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at.
0 Comments
Read More
Leave a Reply. |